MP470 in Treating Patients With Unresectable or Metastatic Solid Tumor or Lymphoma

NCT00504205 · clinicaltrials.gov ↗

NA

Phase

TERMINATED

Status

30

Enrollment

INDUSTRY

Sponsor class

Stopped Withdrawn as trial was never activated by SuperGen

Conditions

Lymphoma
Unspecified Adult Solid Tumor, Protocol Specific

Interventions

DRUG: multitargeted receptor tyrosine kinase inhibitor MP470
OTHER: laboratory biomarker analysis
OTHER: pharmacological study
PROCEDURE: positron emission tomography

Sponsor

Astex Pharmaceuticals, Inc.